Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 13 | 2004 | 1798 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 6 | 2004 | 346 | 0.220 |
Why?
|
| Head and Neck Neoplasms | 6 | 1991 | 1089 | 0.110 |
Why?
|
| Radioimmunodetection | 2 | 2004 | 13 | 0.110 |
Why?
|
| Unrelated Donors | 1 | 2014 | 47 | 0.110 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 67 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 383 | 0.090 |
Why?
|
| Radiotherapy, Conformal | 3 | 2002 | 89 | 0.090 |
Why?
|
| Radiation Injuries | 2 | 2004 | 163 | 0.090 |
Why?
|
| Radiotherapy Dosage | 9 | 2002 | 482 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 372 | 0.080 |
Why?
|
| Radiotherapy | 5 | 2004 | 328 | 0.080 |
Why?
|
| Combined Modality Therapy | 11 | 1999 | 1773 | 0.070 |
Why?
|
| Palliative Care | 1 | 1990 | 273 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 944 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2004 | 2480 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2004 | 204 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2004 | 239 | 0.060 |
Why?
|
| Male Urogenital Diseases | 2 | 2004 | 8 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2004 | 1469 | 0.060 |
Why?
|
| Sarcoma | 3 | 1995 | 225 | 0.060 |
Why?
|
| Adenocarcinoma | 3 | 2002 | 1215 | 0.060 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2004 | 13 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 2 | 2004 | 154 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 154 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 1991 | 1172 | 0.050 |
Why?
|
| Lung Neoplasms | 3 | 1993 | 2463 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 4 | 1999 | 49 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 1993 | 2642 | 0.040 |
Why?
|
| Male | 20 | 2014 | 45870 | 0.040 |
Why?
|
| Radiation Tolerance | 2 | 1990 | 176 | 0.040 |
Why?
|
| Humans | 27 | 2014 | 96127 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 1999 | 144 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1993 | 382 | 0.030 |
Why?
|
| Aged | 13 | 2014 | 20964 | 0.030 |
Why?
|
| Middle Aged | 15 | 2014 | 28363 | 0.030 |
Why?
|
| Aged, 80 and over | 9 | 2004 | 7232 | 0.030 |
Why?
|
| Penile Erection | 1 | 1997 | 22 | 0.030 |
Why?
|
| Patient Selection | 1 | 2000 | 709 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2002 | 639 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 1178 | 0.030 |
Why?
|
| Prostatectomy | 3 | 2004 | 480 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2001 | 2081 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2014 | 38 | 0.030 |
Why?
|
| Busulfan | 1 | 2014 | 43 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 70 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2002 | 3927 | 0.030 |
Why?
|
| Extremities | 1 | 1995 | 179 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2004 | 1195 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 207 | 0.030 |
Why?
|
| Erythropoietin | 1 | 1993 | 91 | 0.020 |
Why?
|
| Fluorouracil | 3 | 1989 | 555 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1990 | 1105 | 0.020 |
Why?
|
| Anemia | 1 | 1993 | 137 | 0.020 |
Why?
|
| Hydroxyurea | 2 | 1989 | 239 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1993 | 156 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 1991 | 98 | 0.020 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2004 | 25 | 0.020 |
Why?
|
| Prognosis | 4 | 2004 | 4033 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1990 | 320 | 0.020 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 1990 | 16 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 1990 | 41 | 0.020 |
Why?
|
| Cell Survival | 2 | 1990 | 1032 | 0.020 |
Why?
|
| Spinal Cord Compression | 1 | 1990 | 47 | 0.020 |
Why?
|
| Brachytherapy | 1 | 1990 | 127 | 0.020 |
Why?
|
| Breast Neoplasms | 3 | 1993 | 3147 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 2001 | 66 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1990 | 151 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 2 | 2004 | 444 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2001 | 910 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2004 | 10286 | 0.020 |
Why?
|
| Chicago | 2 | 2002 | 1503 | 0.020 |
Why?
|
| Methotrexate | 3 | 1993 | 249 | 0.020 |
Why?
|
| Carcinoma | 1 | 1989 | 449 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1990 | 855 | 0.010 |
Why?
|
| Adult | 6 | 2014 | 28718 | 0.010 |
Why?
|
| Cisplatin | 3 | 1993 | 611 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1990 | 793 | 0.010 |
Why?
|
| Female | 9 | 2014 | 50063 | 0.010 |
Why?
|
| Vinblastine | 2 | 1993 | 100 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 2781 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1993 | 304 | 0.010 |
Why?
|
| Newspapers as Topic | 1 | 2000 | 6 | 0.010 |
Why?
|
| Television | 1 | 2000 | 29 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1546 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 1011 | 0.010 |
Why?
|
| Chemoprevention | 1 | 2000 | 93 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 2040 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 192 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2004 | 647 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1990 | 1010 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 3107 | 0.010 |
Why?
|
| Neoplasms | 1 | 1991 | 3250 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 1997 | 79 | 0.010 |
Why?
|
| Probability | 1 | 1997 | 365 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 1981 | 0.010 |
Why?
|
| Radiobiology | 1 | 1995 | 13 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1997 | 599 | 0.010 |
Why?
|
| Cell Line | 2 | 1990 | 2533 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1995 | 297 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 315 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 1999 | 9173 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 134 | 0.010 |
Why?
|
| Cystectomy | 1 | 1993 | 114 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1034 | 0.010 |
Why?
|
| United States | 1 | 2004 | 7767 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1991 | 162 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 872 | 0.010 |
Why?
|
| Quality of Life | 1 | 1999 | 1816 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1993 | 938 | 0.010 |
Why?
|
| Risk Factors | 1 | 2001 | 5960 | 0.000 |
Why?
|
| Esthetics | 1 | 1989 | 50 | 0.000 |
Why?
|
| Stomatitis | 1 | 1989 | 30 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1989 | 136 | 0.000 |
Why?
|
| Adolescent | 2 | 1995 | 9896 | 0.000 |
Why?
|
| Remission Induction | 1 | 1991 | 769 | 0.000 |
Why?
|
| Mastectomy, Segmental | 1 | 1989 | 108 | 0.000 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1989 | 126 | 0.000 |
Why?
|
| Sarcoma, Ewing | 1 | 1988 | 43 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1989 | 235 | 0.000 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1988 | 126 | 0.000 |
Why?
|
| Osteosarcoma | 1 | 1988 | 161 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1989 | 458 | 0.000 |
Why?
|
| Drug Administration Schedule | 1 | 1988 | 873 | 0.000 |
Why?
|
| Survival Rate | 1 | 1989 | 1986 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1993 | 4671 | 0.000 |
Why?
|
| Time Factors | 1 | 1993 | 5585 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1991 | 2422 | 0.000 |
Why?
|